Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage

被引:187
作者
Roviezzo, F
Tsigkos, S
Kotanidou, A
Bucci, M
Brancaleone, V
Cirino, G
Papapetropoulos, A
机构
[1] Univ Athens, George P Livanos Marianthi Simou Labs, Evangelismos Hosp, Dept Crit Care & Pulm Serv, Athens, Greece
[2] Univ Patras, Sch Pharm, Mol Pharmacol Lab, Patras, Greece
[3] Univ Naples Federico II, Fac Pharm, Dept Expt Pharmacol, Naples, Italy
关键词
D O I
10.1124/jpet.105.086553
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiopoietins (Angs) are endothelium-selective ligands that exert most of their actions through the Tie-2 receptor. It is widely accepted that Ang-1 promotes the structural integrity of blood vessels and exhibits anti-inflammatory properties. In contrast, the role of Ang-2 remains less clear because it has been shown to behave as a Tie-2 agonist or antagonist under different experimental conditions. To define the role of Ang-2 in acute inflammation, we studied the effects of recombinant Ang-2 administration in vivo. We show herein that Ang-2, but not Ang-1, induces edema formation in the mouse paw in a dose-dependent manner; the edema seems to be fast-peaking (maximum at 30 min) and resolves within 4 h. The effect of Ang-2 is blocked by the coadministration with a soluble form of the Tie-2 receptor or Ang-1. NO and prostaglandin E-2 levels in mouse paw following the injection of Ang-2 remained unaltered, suggesting that the action of Ang-2 does not involve these mediators. In addition, Ang-2 exerted a weak stimulatory effect on leukocyte migration in the mouse paw. Similarly, Ang-2 injected into the mouse air pouch produced only a modest effect on cell extravasation that peaked at 30 min. However, when cell migration was elicited using zymosan, Ang-2 significantly inhibited leukocyte migration. We conclude that Ang-2 by itself stimulates the extravasation of cell-poor fluid, but in the presence of ongoing inflammation it reduces cellular infiltration in tissues.
引用
收藏
页码:738 / 744
页数:7
相关论文
共 36 条
[11]   Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF [J].
Holash, J ;
Maisonpierre, PC ;
Compton, D ;
Boland, P ;
Alexander, CR ;
Zagzag, D ;
Yancopoulos, GD ;
Wiegand, SJ .
SCIENCE, 1999, 284 (5422) :1994-1998
[12]   Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway [J].
Kim, I ;
Kim, JH ;
Moon, SO ;
Kwak, HJ ;
Kim, NG ;
Koh, GY .
ONCOGENE, 2000, 19 (39) :4549-4552
[13]   Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression [J].
Kim, I ;
Moon, SO ;
Park, SK ;
Chae, SW ;
Koh, GY .
CIRCULATION RESEARCH, 2001, 89 (06) :477-479
[14]   Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-κB activation in endothelial cells [J].
Kim, I ;
Moon, SO ;
Kim, SH ;
Kim, HJ ;
Koh, YS ;
Koh, GY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (10) :7614-7620
[15]   Angiopoietin-1 induces sprouting angiogenesis in vitro [J].
Koblizek, TI ;
Weiss, C ;
Yancopoulos, GD ;
Deutsch, U ;
Risau, W .
CURRENT BIOLOGY, 1998, 8 (09) :529-532
[16]   Biological characterization of angiopoietin-3 and angiopoietin-4 [J].
Lee, HJ ;
Cho, CH ;
Hwang, SJ ;
Choi, HH ;
Kim, KT ;
Ahn, SY ;
Kim, JH ;
Oh, JL ;
Lee, GM ;
Koh, GY .
FASEB JOURNAL, 2004, 18 (11) :1200-1208
[17]   Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses [J].
Lemieux, C ;
Maliba, R ;
Favier, J ;
Théorêt, JF ;
Merhi, Y ;
Sirois, MG .
BLOOD, 2005, 105 (04) :1523-1530
[18]   Role of protein kinase Cζ in thrombin-induced endothelial permeability changes:: inhibition by angiopoietin-1 [J].
Li, XC ;
Hahn, CN ;
Parsons, M ;
Drew, J ;
Vadas, MA ;
Gamble, JR .
BLOOD, 2004, 104 (06) :1716-1724
[19]   Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis [J].
Maisonpierre, PC ;
Suri, C ;
Jones, PF ;
Bartunkova, S ;
Wiegand, S ;
Radziejewski, C ;
Compton, D ;
McClain, J ;
Aldrich, TH ;
Papadopoulos, N ;
Daly, TJ ;
Davis, S ;
Sato, TN ;
Yancopoulos, GD .
SCIENCE, 1997, 277 (5322) :55-60
[20]  
Malik AB, 1996, PHARMACOL REV, V48, P213